Comparative Pharmacology
Head-to-head clinical analysis: LORAZEPAM INTENSOL versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORAZEPAM INTENSOL versus PAXIPAM.
LORAZEPAM INTENSOL vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
0.5-2 mg orally every 6-8 hours as needed. Maximum 4 mg/day.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in elderly (15-20 hours) and patients with hepatic impairment (up to 30-40 hours).
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Renal excretion of glucuronide conjugates; <1% unchanged drug excreted renally. Fecal elimination accounts for approximately 10% of administered dose.
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine